Saniona AB (publ) (STO:SANION)

Market Cap	1.09B
Revenue (ttm)	334.67M
Net Income (ttm)	188.71M
Shares Out	136.09M
EPS (ttm)	1.76
PE Ratio	4.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	539,316
Average Volume	505,204
Open	8.29
Previous Close	8.21
Day's Range	7.98 - 8.40
52-Week Range	1.75 - 9.91
Beta	0.80
RSI	61.04
Earnings Date	Apr 30, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION